Hacker News Reader

They evaluated "the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein (ChAd-SARS-CoV-2-S) in challenge studies with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor" https://www.cell.com/cell/fulltext/S0092-8674(20)31068-0

View on HN

Just to clarify — the vaccine uses as its backbone a type of adenovirus that typically infects chimpanzees, modified by the addition of pieces from SARS-CoV-2, but the experiments testing efficacy are performed in mice (specifically, a type of mice engineered to express humanized ACE2).

This vaccine has not been tested in chimpanzees (and actually such experiments would probably be a challenge, since they may have existing immunity to the backbone adenovirus).

(edit: parent comment initially mentioned experiments in chimpanzees rather than mice)

what the hell? that is quite odd, considering they have quotes from a professor at the university in the press release talking about mice as well... and it's not as though the press release is old or anything. shrug

Reply on news.ycombinator.com